Regulus Therapeutics Inc. (RGLS)

$0.31

+0.03 (+12.52%)
Rating:
Recommendation:
Buy
Symbol RGLS
Price $0.31
Beta 2.204
Volume Avg. 2.24M
Market Cap 45.254M
Shares () -
52 Week Range 0.16-1.48
1y Target Est -
DCF Unlevered RGLS DCF ->
DCF Levered RGLS LDCF ->
ROE -67.08% Strong Sell
ROA -46.76% Strong Sell
Operating Margin -
Debt / Equity 23.85% Neutral
P/E -
P/B 0.92 Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest RGLS news


Mr. Joseph Hagan
Healthcare
Biotechnology
NASDAQ Capital Market

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.